GGrantIndex
← Search

High Throughput Screening

$2,734P30FY2018CANIH

Sloan-Kettering Inst Can Research, New York NY

Investigators

Linked publications, trials & patents

Trial NCT03699631Trial NCT02595918Trial NCT02417701Trial NCT02219737Trial NCT02152995Trial NCT01979523Trial NCT01947023Trial NCT01902160Trial NCT01705340Trial NCT01643278Trial NCT01638546Trial NCT01587352Trial NCT01585805Trial NCT01326702Trial NCT01281865Trial NCT01196416Trial NCT01154452Trial NCT01143402Trial NCT01119599Trial NCT01051557Trial NCT01026623Trial NCT01016015Trial NCT00957905Trial NCT00866177Trial NCT00729157Trial NCT00639509Trial NCT00601692Trial NCT00589472Trial NCT00570401Trial NCT00567229Trial NCT00550628Trial NCT00541034Trial NCT00528450Trial NCT00522301Trial NCT00521014Trial NCT00519974Trial NCT00514254Trial NCT00498927Trial NCT00483678Trial NCT00474994Trial NCT00471679Trial NCT00471601Trial NCT00470574Trial NCT00470470Trial NCT00462982Trial NCT00462501Trial NCT00459875Trial NCT00458705Trial NCT00453310Trial NCT00450827Trial NCT00416351Trial NCT00404365Trial NCT00398138Trial NCT00397904Trial NCT00369174Trial NCT00354679Trial NCT00334893Trial NCT00324480Trial NCT00245102Trial NCT00104845Trial NCT00090337Trial NCT00089245Trial NCT00087009Trial NCT00072345Trial NCT00072319Trial NCT00070057Trial NCT00067015Trial NCT00062374Trial NCT00059891Trial NCT00058253Trial NCT00054132Trial NCT00046917Trial NCT00040898Trial NCT00040872Trial NCT00039286Trial NCT00037011Trial NCT00036933Trial NCT00028730Trial NCT00024258Trial NCT00023764Trial NCT00020891Trial NCT00016146Trial NCT00014534Trial NCT00014469Trial NCT00008294Trial NCT00008242Trial NCT00006044Trial NCT00004245Trial NCT00004066Trial NCT00003923Trial NCT00003819Trial NCT00003173Trial NCT00003023Trial NCT00002981Trial NCT00002930Trial NCT00002766Trial NCT00002738Trial NCT00002718Trial NCT00002663Trial NCT00002558

Abstract

The High-throughput Screening Core Facility (HTSCF) was established in 2003 to support the Institution's growth in chemical biology and functional genomics. The HTSCF's ongoing mission continues to support such efforts. Bioactive compounds are used as chemical tools to probe biological processes. The identification of novel molecules requires a broad range of tools including robust assays, large collections of chemicals, HTS technologies, and knowledge in hit validation and characterization steps. The HTSCF has modern robotics, custom built screening data management databases, chemical screening libraries, RNAi screening libraries, assay development and industrialization expertise, screening data analysis and management. The Core is equipped with two custom-built linear track robotic platforms harboring several dispensers, microtiter plate readers, automated microscopes among other instrumentation enabling both invitro target based and cell based assays to be routinely performed. Screening data acquisition and management is handled through a suite of custom built software. The compound library has grown to 400K chemicals; and contains a wide variety of natural products. The RNAi libraries have also grown to include both siRNA and shRNA capabilities covering 22K genes. Glycerol stocks of individual shRNA hairpins are provided as a service. One example of important work facilitated by this work was a screen against mutant EGFR in human lung cancer cell lines by the Varmus lab. The screening efforts led to the identification and characterization of four classes of small molecules overcoming the mutations. The broad range of services and collaborative work provided by the (HTSCF) has supported the research of 48 investigators in the past year. During the past grant period the work of the Core has contributed to 27 publications of researchers from 8 research programs.

View original record on NIH RePORTER →